Urologix
Our session will provide attendees with information about how adopting both Cooled ThermoTherapy and Prostiva RF Therapy for the treatment of BPH will help them safely and effectively treat a broader patient population.
Minneapolis, MN (PRWEB) March 25, 2014
Urologix, Inc. (OTCQB:ULGX), the market leader for In-Office BPH Therapy, today announced it will participate in “The 2014 Scottsdale Summit” presented by the Rush University Medical Center Department of Urology, in collaboration with UT Southwestern and Mayo Clinic Arizona. The event is taking place the JW Marriott Camelback in Scottsdale, Arizona from March 28-30.
This post-graduate conference is a multi-institutional, collaborative effort to provide advanced-level, hands-on training for the general urologist. Through didactic presentations, case conferences, and hands on simulation, attendees will interact with expert specialists to gain instruction in the diagnosis, evaluation and management of difficult urologic problems, including Benign Prostatic Hyperplasia or BPH.
The conference agenda includes ‘Hands-On Simulation Sessions’ which will include Urologix’s in-office BPH Therapies, Cooled ThermoTherapy™ and Prostiva® RF Therapy. These sessions are scheduled for Saturday afternoon, March 29 and will feature Robert G. Pugach, MD - a pioneer in the area of in-office BPH therapy - and Medical Director of Pacific Coast Urology Medical Center.
“This conference is an excellent opportunity for urologists to interact with their peers to learn more about treating serious urologic problems.” said Greg Fluet, Chief Executive Officer of Urologix. “Our session will provide attendees with information about how adopting both Cooled ThermoTherapy and Prostiva RF Therapy for the treatment of BPH will help them safely and effectively treat a broader patient population, in the office setting, delivering very cost effective outcomes.“
BPH, also known as enlarged prostate, affects the majority of men as they age and can create bothersome symptoms which significantly impact quality of life. This disease continues to be predominantly treated with medications; however, research has shown that drugs are not always effective and can produce unpleasant side effects. Urologix’s in-office BPH Therapies, Cooled ThermoTherapy and Prostiva RF Therapy, the marketing leading non-surgical options, have proven their results through numerous clinical studies and are recommended treatment options within American Urology Association guidelines. To find out more about Urologix in-office BPH therapies, visit http://www.urologix.com.
About Urologix
Urologix, Inc., based in Minneapolis, develops, manufactures, markets and distributes minimally invasive medical products for the treatment of obstruction and symptoms due to Benign Prostatic Hyperplasia (BPH). Urologix’s Cooled ThermoTherapy produces targeted microwave energy combined with a unique cooling mechanism to protect healthy tissue and enhance patient comfort. The Prostiva RF Therapy System delivers radio frequency energy directly into the prostate destroying prostate tissue, reducing constriction of the urethra, and thereby relieving BPH symptoms. Both of these therapies provide safe, effective and lasting relief of obstruction and symptoms due to BPH. Prostiva is a registered trademark of Medtronic, Inc., used under license. All other trademarks are the property of Urologix.
Federal USA law restricts these devices to sale by or on the order of a physician. For more complete information about the benefits, risks and contraindications associated with Cooled ThermoTherapy and Prostiva RF Therapy, please refer to http://www.urologix.com.
If you would like more information on this topic, please contact Susan Overby at 763-745-1540 or soverby(at)urologix(dot)com. To learn more about Urologix and its products and services, visit http://www.urologix.com.
The Urologix logo and other media assets are available at http://www.urologix.com/clinicians/resource-library.php.
Urologix Media Contact
Susan Overby
763-745-1540
soverby(at)urologix(dot)com
Urologix Investor Relations Contact
Brian Smrdel
(763) 475-7696
bsmrdel(at)urologix(dot)com